GIT Therapeutics

As a pharma company Spinoff, GIT Therapeutics is transforming the future of healthcare by decoding oral drug delivery. Our breakthrough platform enables precise, sustained treatment - delivered exactly where and when it’s needed, eliminating variability, reducing side effects, and replacing invasive therapies. We are committed to setting new standards of care for hundreds of millions worldwide, creating a healthier tomorrow through breakthrough innovation. Our proprietary TARDIS oral delivery system uniquely targets the digestive system with sustained-release drug therapy to maximize clinical efficacy, minimize side effects, creating a paradigm shift in therapeutic outcomes, unlocking new market potential in precision medicine. By obtaining targeted, time controlled sustained release therapy, we aim to address critical unmet needs across major multi-billion-dollar markets , including Parkinson’s disease, MS, IBD (Crohn’s, Ulcerative Colitis), GI infections (H. Pylori, CDI), Celiac disease, and Obesity management. TARDIS drug delivery system is uniquely engineered to be retained in the stomach or the impossible to efficiently target ileocecal valve (ICV) for a predefined time ensuring sustained, localized, & safe medical therapy. This capability addresses a critical challenge in oral drug delivery - the short and unpredictable drug residence time at key GI regions that highly limits efficacy and safety profiles of current drug treatments.

GIT Therapeutics was founded in 2024 by Erez Cohn (Co-Founder & CEO), Avshalom Ben Manachem (Co-Founder & CTO), Ilan Zalit Zalit (Co-founder & CSO ).

GIT Therapeutics operates in Health Tech & Life Sciences, with core technologies in Biologicals, Materials & Substances. Target customers: Healthcare & Life Sciences.

GIT Therapeutics is based in Tel Aviv-Yafo, Israel, Center District.